Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia
Pediatric Pulmonology · 2023
DOI: 10.1002/ppul.26426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Yu-Shan He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Intensive Care Unit, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Azithromycin, Pneumonia, Mycoplasma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research and Application of Clinical Diagnosis and Treatment Technology in Capital.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
With the increase in macrolide‐resistant M. pneumoniae infections, off‐label use is difficult to avoid. This study assessed the safety of moxifloxacin in pediatric patients with severe refractory M. pneumoniae pneumonia (SRMPP).
Methods
We retrospectively reviewed the medical records of children with SRMPP between January 2017 and November 2020 at Beijing Children's Hospital. They were divided into the moxifloxacin group and azithromycin group according to whether or not moxifloxacin was used. The clinical symptoms, radiographs of both knees, and cardiac ultrasounds of the children were collected after drug withdrawal for at least 1 year. A multidisciplinary team reviewed all adverse events and determined their relationship with moxifloxacin.
Results
A total of 52 children with SRMPP were included in this study (31 in the moxifloxacin group and 21 in the azithromycin group). In the moxifloxacin group, four patients had arthralgia, one had joint effusion, and seven had heart valve regurgitation. In the azithromycin group, three patients had arthralgia, one had claudication, and one had heart valve regurgitation; no obvious knee abnormalities were observed in the radiographs. No statistically significant differences in clinical symptoms or imaging findings were found between the groups. As for the adverse events, 11 patients in moxifloxacin group were deemed to be doubtfully related and one possibly related to moxifloxacin; in the azithromycin group, four patients were regarded to be doubtfully related to azithromycin and one not related.
Conclusion
Moxifloxacin was well tolerated and safe for treating SRMPP in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Intensive Care Unit, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
- Department of Pharmacy, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
ORCID-Profile: Yu-Shan He
Förderung
- Research and Application of Clinical Diagnosis and Treatment Technology in Capital
Zitieren
APA
He, Y. S., Yang, M., Liu, G., Ji, J., & Qian, S. Y. (2023). Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26426
Vancouver
He YS, Yang M, Liu G, Ji J, Qian SY. Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26426
BibTeX
@article{He2023,
author = {He, Yu-Shan and Yang, Mei and Liu, Gang and Ji, Jian and Qian, Su-Yun},
title = {Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia},
journal = {Pediatric Pulmonology},
year = {2023},
doi = {10.1002/ppul.26426}
}
EUVIMED